Galactooligosaccharide & Aging

Status Recruiting

Clinical Trial Summary

Sarcopenia is a progressive muscle disease, most commonly affecting older individuals, that is categorised by 1) low muscle strength, 2) low muscle quantity or quality, and 3) low physical performance. This disease has several negative implications for human health, including an increased risk of falls, fractures, mobility limitations, and mortality. Sarcopenia also imposes significant burden on healthcare systems. For example, it was estimated that a 10% reduction in the prevalence of sarcopenia would save the US healthcare system $1.1 billion per year. Strategies to reduce the incidence and severity of sarcopenia are therefore of great interest. One potential cause for sarcopenia is long-term, low-level inflammation, which can occur for a number of reasons. One cause may relate to the intestinal wall becoming more susceptible to leaking of toxic particles. Evidence suggests that prebiotic supplementation can reduce this 'leakage'. Galactooligosaccharide (a prebiotic) has previously been shown to reduce inflammation in elderly individuals. The investigators hypothesise that galactooligosaccharide will improve physical function in the elderly indirectly via a reduction in inflammation. This will be a randomised, placebo-controlled, double-blind, parallel study. 32 elderly individuals (65-85 years; mix of males and females) will be randomised to one of two groups, GOS or PLACEBO. The GOS group will supplement their diet with 2.9 g galactooligosaccharide per day for 16 weeks in the form of one sachet (3.65 g) of Bimuno® Daily. The PLACEBO group will supplement with 3.65 g maltodextrin per day for 16 weeks. The study will involve one screening visit and two main trials (baseline and 16 weeks). For the main trials, participants will complete the short physical performance battery (SPPB) and handgrip strength test. In addition, participants will provide blood, urine and faecal samples, as well as a dual-energy x-ray absorptiometry (DEXA), and a peripheral quantitative computed tomography (pQCT) scan.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Muscle Loss

Clinical Trial Details

NCT number	NCT06411964
Study type	Interventional
Source	University of Bath
Contact	Adam J Collins
Phone	07710611694
Email	ac3413@bath.ac.uk
Status	Recruiting
Phase	N/A
Start date	May 2, 2024
Completion date	October 6, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04207359` - Effects of Creatine Supplementation in Breast Cancer Survivors	N/A
Enrolling by invitation	`NCT05215964` - The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Completed	`NCT05999266` - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Completed	`NCT05531305` - Longitudinal Changes in Muscle Mass After Intensive Care	N/A
Completed	`NCT04597983` - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists	N/A
Completed	`NCT01292395` - Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency	N/A
Completed	`NCT00755638` - A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers	Phase 1
Completed	`NCT04546048` - The Early Strength Training Program in Post-transplant Liver Cases	N/A
Recruiting	`NCT05570474` - Effect of Protein Supplementation on Fat Free Mass Preservation After Bariatric Surgery	N/A
Completed	`NCT05497960` - Vivo Prediabetes Study: Online, Live, and Interactive Strength Training for Older Adults With Prediabetes	N/A
Completed	`NCT04422665` - Preventing Bed-rest Induced Muscle Loss in the Elderly	N/A
Completed	`NCT05088304` - GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer
Completed	`NCT03400046` - The Correlation Between Nutrients and Muscle Mass	N/A
Completed	`NCT01894737` - The Effect of Creatine on Muscle Loss	N/A
Completed	`NCT01714479` - Skeletal Muscle Response to Amino Acids and Load Carriage Exercise	N/A
Completed	`NCT05072652` - Short Term Immobilization of the Lower Limb	N/A
Completed	`NCT04661618` - A Randomized-Control Study of Gym Tonic's Community Based Strength Training Intervention.	N/A
Completed	`NCT05009654` - The Effect of Leucine on Carnitine Transport to Skeletal Muscle	N/A
Recruiting	`NCT05795556` - Biomarkers of Sarcopenia and Frailty in Geriatric Patients
Completed	`NCT04151108` - Biomarkers for Length of Hospital Stay and Loss of Muscle Mass and Function in Old Medical Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Galactooligosaccharide and Aging

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms